Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: The Michigan Department of Health and Human Services says it's working with the Macomb County Health Department to investigate the illnesses at McLaren Macomb Hospital in Mount Clemens. The departments say six of the seven Legionnaires' cases have been reported at the hospital since mid-September. Both agencies are investigating the source of the disease and whether there are more infected people. The hospital is cooperating with the investigation and plans to increase water testing to look for any signs of the Legionella bacteria that causes the illness. Legionnaire's is a flu-like illness contracted when infected water vapor is inhaled. The elderly and people with weakened immune systems can be particularly susceptible.
Example Output: Michigan probes Detroit-area hospital's 7 Legionnaires cases.

Example Input: Six patients were still responding at 7.5 months of follow-up, according to research presented in San Diego at the annual meeting of the American Society of Hematology (ASH). The highest trial dose was discontinued due to toxicity. Nearly a third of trial patients developed serious infections and other side effects included nerve damage and liver failure. Amgen said AMG420, which targets a protein linked to multiple myeloma known as BCMA, has been given fast track status by the U.S. Food and Drug Administration. "Based on these data, we plan to open an expanded trial," David Reese, Amgen's head of research and development, said in an interview. "We want to begin exploring quickly enrollment in earlier lines of therapy." Amgen's pipeline of bispecific antibodies, which are designed to attach to a cancer cell and an immune cell, bringing them together so the body's immune system can kill the cancer, are a cornerstone of the biotech company's oncology research. Other companies are exploring different ways to attack the same BCMA target, including bluebird bio Inc, Celgene Corp and Johnson & Johnson. Earlier at the ASH meeting, bluebird and Celgene presented early trial data showing that experimental cell therapy bb21217 induced responses in 10 out of 12 heavily pre-treated myeloma patients. Bb21217 is a next-generation version of bb2121, the companies' more advanced, but still experimental therapy in a class called CAR-T that requires harvesting a patient's own disease-fighting T-cells, modifying them in a laboratory so they target specific proteins on cancer cells and infusing them back into the patient. The manufacturing process for bb21217 is designed to improve the persistence of the altered cells. J&J, which licensed BCMA-directed CAR-T LCAR-B38M from a unit of China-based GenScript Biotech Corp, on Monday presented updated results from a Chinese study of the cell therapy in 57 previously treated myeloma patients. It showed that 88 percent of patients responded to the treatment, and 74 percent achieved remission. J&J is currently enrolling patients in an international study aimed at validating those findings. Amgen has suggested the "off the shelf" nature of its antibody platform could be an advantage from both a clinical and commercial standpoint, but oncologists say more data is needed. Trial patients are hospitalized for their first cycle of AMG420, after which they receive the drug by continuous 24-hour infusion for four weeks, followed by two weeks off therapy, for up to 10 cycles. Amgen has another BCMA-targeting antibody that lasts longer in the body, requiring less frequent infusions, but that research is at an earlier stage. In the current study, 42 patients with multiple myeloma that worsened after at least two prior treatments were given AMG420 at varying doses. A total of 13 patients responded to the treatment, including seven who achieved remission. Of the 20 patients with serious adverse events, 17 required hospitalization and four had prolonged hospitalization.
Example Output: Amgen antibody shows promise in myeloma trial, gets FDA fast track.

Example Input: Despite being used both recreationally and medicinally for millennia, the mechanisms by which cannabis affects the human body have only recently come to light. The most significant development in this body of work is the discovery of what scientists term the "endocannabinoid system," a collection of chemical pathways found in mammals whose existence wasn't demonstrated until the 1990s. The endocannabinoid system is made up of specific receptors that are primarily affected by chemicals already in your body endocannabinoids. As it turns out, many of the chemicals in cannabis, termed "phytocannabinoids", are nearly identical to the endocannabinoids already present and can therefore also affect these receptors as well if they make their way into your bloodstream. The most famous of these chemicals is tetrahydrocannabinol (commonly known as THC), which produces the psychoactive "high" people seek when they use the drug recreationally. Later research has yielded the discovery of a plethora of other phytocannabinoids that do not produce a psychoactive effect, but do demonstrate therapeutic potential. The most notable of these "other" chemicals is cannabidiol (referred to as CBD), which studies suggest has strong pain-relieving and anti-inflammatory properties, and has been shown essentially to halt seizures caused by the neurologic condition Dravet's Syndrome. A 2008 paper published in Proceedings of the National Academy of Sciencessuggested that CBD acted on a previously undescribed endocannabinoid receptor, GPR55, and that this receptor likely plays a role in the regulation of bone mass by inhibiting the growth of cells osteoclasts that promote the resorption of bone minerals: Our observations also suggest that CBD can inhibit bone resorption in vivo via modulation of GPR55 signaling. They go on to suggest, however, that because THChas the opposite effect on this receptor, that this interaction may negate the positive effects on bone density caused by CBD: Our observations suggest that blocking GPR55 also may have direct beneficial effects on bone turnover in arthritic or metabolic bone diseases. Finally, although CBD is a major constituent of cannabis, it remains to be determined whether cannabis smoking may increase bone density, because [THC], another constituent, also is thought to be a GPR55 ligand and may oppose the effects of CBD. In this context, two studies took a closer look at the possible mechanisms by which CBD, specifically, might help bones heal from a fracture. A 2014study published in Biochemical Pharmacology that utilized isolated cells suggested that CBD may activate a receptor in the endocannabinoid system (CB2) that enhances the migration of mesenchymal stem cells (which play a role in creating calcified bones) to the site of the fracture. A 2015study published in the Journal of Bone and Mineral Research reaffirmed the possibility that CBD can help with healing fractures: Here we report that the major non-psychoactive cannabis constituent, cannabidiol (CBD), enhances the biomechanical properties of healing rat mid-femoral fractures. The maximal load and work-to-failure, but not the stiffness, of femurs from rats given a mixture of CBD and 9-tetrahydrocannabinol (THC) for 8 weeks were markedly increased by CBD. They found that, indeed, CBD increased the strength of the healed broken femurs of laboratory rats. The authors noted that CBD, with all other constituents removed, was more effective. Theysuggest a different mechanism for this effect: CBD increases the expression of a gene that codes for a series of reactions that results in the production of collagen, which is then transformed into harder bone material, a process termed collagen cross-linking. Each of these three mechanisms that link CBD to bone physiology has support in the scientific community, as attested to by their inclusion in a September 2016 review of phytocannabinoid pharmacology in the journal Physiological Reviews. It is important to note, however, that CBD specifically, and not the cannabis plant as a whole, is implicated in the therapeutic effects on bones. As such, consuming just any cannabis would not necessarily be effective. Any treatment would require an effort to isolate or increase the concentration of CBD and remove or reduce THC.
Example Output:
Scientific studies support the conclusion that marijuana can play a role in healing broken bones.